A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
By M. Tuszynski, L. Thal, M. Pay, David P. Salmon, H. U, R. Bakay, P. Patel, A. Blesch, H. Vahlsing, G. Ho and 8 more. Nature Medicine, 2005
1,045 citations recorded by the source corpus.
Subfields: Cellular and Molecular Neuroscience, Pharmacology
View Paper: https://www.semanticscholar.org/paper/18eff3bab2aa36ef46b095c495a9f55004d1169f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cellular and Molecular Neuroscience
Citations in the corpus
- Potential therapeutic uses of BDNF in neurological and psychiatric disorders (2011, background): “Based on this therapeutic potential, growth factors have been evaluated in patients with various neurological disorders, including amyotrophic lateral sclerosis (ALS), peripheral neuropathy, Parkinson's disease and Alzheimer's diseas”
- Alzheimer's Disease: Targeting the Cholinergic System (2016, background): “Clinical trials indicate that NGF can rescue cholinergic neurons and stabilize the rate of cognitive decline in AD patients [263, 264].”
- Stem cells for the treatment of neurological disorders (2006, result): “In support of this approach, basal forebrain grafts of fibroblasts that produce nerve growth factor (NGF) — which counteracts cholinergic neuronal death, stimulates cell function and improves memory in animal models — have been of some benefit in patients with A”
- Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. (2013, background): “, 2006), and neuroprotective approaches (Tuszynski et al., 2005) for AD therapy.”
- Cell death in the nervous system (2006, background): “A number of approaches have been taken to deliver nerve growth factor (NGF) to patients with AD, the most recent being by means of genetically engineered fibroblasts in a phase I tria”
- GDNF, NGF and BDNF as therapeutic options for neurodegeneration. (2013, background): “The concept of NGF protein administration as an AD therapeutic was translated to a Phase I clinical trial initiated in 2001 (Tuszynski et al., 2005).”